Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on July 18, 2024, covering events occurring on July 17, 2024. The Company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol "JAGX".
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on a corporate agreement.
Material Changes
On July 17, 2024, the Company entered into the "Third ATM Amendment" to its At the Market Offering Agreement dated December 10, 2021. Key changes include:
- New Manager: Lucid Capital Markets, LLC ("Lucid") was added as a co-manager alongside the existing manager, Ladenburg Thalmann & Co. Inc. ("Ladenburg").
- Effective Period: Lucid's participation as a manager is effective from July 17, 2024, through September 30, 2024.
- Future Structure: Unless extended or amended prior to September 30, 2024, Ladenburg will revert to being the sole manager, and Lucid will cease to be a manager under the agreement.
- Documentation: A prospectus supplement was filed with the SEC to reflect these changes.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It includes standard legal disclaimers stating that the report does not constitute an offer to sell or a solicitation of an offer to buy securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the full text of the Third ATM Amendment attached as Exhibit 10.1 for specific terms regarding commission rates and obligations.
- Confirm whether the agreement is extended beyond September 30, 2024, in future filings.
- Review the filed prospectus supplement for updated disclosure regarding the offering structure.